Floatz logo

Bortezomib

Cancer, Gall Bladder

Leaf Vertical Inc.Small moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

30 Active assets in the Cancer, Gall Bladder cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Lisata Therapeutics, Inc.
Phase 2BBB
Eloxatin
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Capecitabine
Merck Sharp & Dohme LLC
Phase 3BB
Docetaxel
Merck Sharp & Dohme LLC
Phase 2BB
Desflurane
Tokyo Medical and Dental University
Phase 4BB

View all 50 →

Same molecule, other indications

Bortezomib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
71 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →